Constellation Pharmaceuticals, Inc.
PHARMACOKINETIC ENHANCEMENT OF EZH2 INHIBITORS THROUGH COMBINATION THERAPIES

Abstract:

Provided herein are pharmaceutical composition comprising an effective amount of (R)--N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methy- l)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-- 3-carboxamide, or a pharmaceutically acceptable salt thereof and an effective amount of cobicistat, or a pharmaceutically acceptable salt thereof. Also provided s the use of an effective amount of (R)--N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methy- l-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxam- ide, or a pharmaceutically acceptable salt thereof and an effective amount of cobicistat, or a pharmaceutically acceptable salt thereof for treating cancer.